Scroll to top

Scroll to top

Skip to content

Home
About
Pipeline
News
Publications
Investors
Career
Contact

Home
About
Pipeline
News
Publications
Investors
Career
Contact

News Releases

Home
Investors
News Releases

Investor Relations

IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact

News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Month Year

Su	Mo	Tu	We	Th	Fr	Sa

Investor Alerts

Year Keywords

Advanced Search

Search

Search Headlines Only

From

To

Asset Types

Photos Video Audio Documents Events Standard

November 13, 2024

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
November 7, 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 31, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
October 29, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November
October 22, 2024

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
September 18, 2024

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
September 4, 2024

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
August 28, 2024

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
August 8, 2024

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 1, 2024

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
July 24, 2024

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
July 9, 2024

Immunic Appoints Jason Tardio as Chief Operating Officer and President
May 28, 2024

Immunic to Participate in Industry and Scientific Conferences in June
May 8, 2024

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6, 2024

Immunic to Participate in Investor and Scientific Conferences in May
May 1, 2024

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
April 30, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
April 4, 2024

Immunic to Host MS R&D Day and Participate in Investor Conferences in April
March 20, 2024

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
March 7, 2024

Immunic to Participate in Investor and Scientific Conferences in March
February 29, 2024

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
February 22, 2024

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
February 15, 2024

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 1, 2024

Immunic to Participate in Investor and Scientific Conferences in February
January 5, 2024

Immunic Highlights 2023 Accomplishments and Upcoming Milestones
January 5, 2024

Immunic, Inc. Announces Private Placement of up to $240 Million
November 21, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
November 14, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 7, 2023

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
November 2, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
October 26, 2023

Immunic to Participate in Scientific and Industry Conferences in November
October 16, 2023

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
October 15, 2023

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
October 11, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
October 9, 2023

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
October 4, 2023

Immunic to Participate in Scientific Conferences in October
September 6, 2023

Immunic to Participate in Industry and Investor Conferences in September
August 17, 2023

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
August 3, 2023

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 1, 2023

Immunic to Participate in Investor and Scientific Conferences in August
July 27, 2023

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
June 29, 2023

Immunic to Participate in Scientific and Investor Conferences in July
May 30, 2023

Immunic to Participate in Scientific and Investor Conferences in June
May 17, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 11, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
May 6, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
May 4, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
April 27, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
April 26, 2023

Immunic to Participate in Investor and Scientific Conferences in May

Show 5 10 25 50 100 per page

«
1
2
3
4
»

Immunic, Inc.

1200 Avenue of the Americas
Suite 200
New York, NY 10036, USA

Phone: +1 332 2559811
Email: info@imux.com

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing
Germany

Phone: +49 89 2080 477 00
Email: info@imux.com

Stay in Touch

Contact Us

About
Pipeline

Vidofludimus Calcium
IMU-856
IMU-381

News
Publications
Investors

Career
Contact
Legal Notice

Accessibility Statement
Privacy Policy
Change Privacy Settings

© 2024, Immunic Therapeutics

All rights reserved.